Evaluation of an Outpatient Model for Treatment of Acute Myeloid Leukemia

Andrew Aw, Mitchell Sabloff, Dawn Sheppard, David Allan, Harold Atkins, Isabelle Bence-Bruckler, Carolyn Faught, Lothar Huebsch, Jason Tay, Kate Duke, Timothy Ramsay, Chris Bredeson

Abstract


Background: In January 2012, our center developed an ambulatory model for acute myeloid leukemia (AML) patients receiving post-induction chemotherapy. The purpose of this study was to evaluate the feasibility and safety of the outpatient leukemia program at our center.

Methods: A retrospective review of all consecutive AML patients receiving a first cycle of consolidation chemotherapy in the outpatient program in 2012 was compared to similarly managed patients primarily in the inpatient setting in 2010.

Results: The 2012 cohort spent more days as outpatients in comparison to the 2010 cohort (median (range): 15.5 (0 - 27) vs. 0 (0 - 10), days, P = 0.002). There was no difference between the two cohorts in terms of median overall observation time (time from start of chemotherapy until discharged to clinic), transfusion requirements, days spent neutropenic or days spent febrile. There were no documented episodes of Clostridium difficile, clinically significant bleeding, venous thromboembolism, or death in either cohort.

Conclusions: Outpatient management of AML patients receiving post-induction chemotherapy was feasible in this group of carefully selected individuals, liberating limited and costly inpatient resources for more appropriate patients.




J Hematol. 2016;5(1):1-7
doi: http://dx.doi.org/10.14740/jh235w

 


Keywords


Acute myeloid leukemia; Consolidation chemotherapy; Antineoplastic combined chemotherapy protocols; Outpatients; Ambulatory care; Multidisciplinary care

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!